Adam Waldman
Chief Commercialization OfficerMr. Adam Waldman has been Chief Commercialization Officer of TG Therapeutics, Inc. since June 4, 2018. Mr. Waldman has extensive experience commercializing products in oncology and hematology, most recently as the Head of US Hematology-Oncology Marketing at Celgene Corporation, and has an extensive track record of successfully launching multiple brands. Mr. Waldman joined TG Therapeutics with more than 20 years of experience in the biotechnology and life science industries. Most recently, Mr. Waldman served as the Head of US Hematology-Oncology Marketing at Celgene Corporation where he spent the past 13 years in various roles of increasing responsibility in sales, marketing and new product strategy. Adam brings extensive experience and a proven track record of success building high performing teams and launching transformational products in both hematology and oncology. Prior to Celgene, Mr. Waldman was at Schering Plough where he was responsible for coordinating the global marketing strategy for multiple oncology products. Mr. Waldman holds an MBA in Finance from the University of Rochester, Simon Business School as well as a B.S. in Biological Science from Rutgers College.
Positions
- Company NameTG Therapeutics, Inc.Stock CodeTGTXPositionChief Commercialization OfficerColleagues
- MSMichael S. WeissChairman, CEO & President
- SASean A. PowerCFO, Corporate Secretary & Treasurer
- JBJenna BoscoSenior Vice President of Corporate Communications
- LNLaurence N. CharneyLead Independent Director
- KHKenneth HobermanIndependent Director
- SLSagar LonialIndependent Director
- YEYann EchelardIndependent Director
